We are live on ! Find out more
ACM

Ayer Capital Management Portfolio holdings

AUM $26.8M
This Fund
S&P 500
This Quarter Est. Return
-20.92%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.45M
AUM Growth
-$13.9M
Cap. Flow
-$13.9M
Cap. Flow %
-313.56%
Top 10 Hldgs %
100%
Holding
2
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CELGZ
Celgene Corporation Contingent Value Rights
CELGZ
+$11.2M
2
PTCT icon
PTC Therapeutics
PTCT
+$2.72M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
1
PTC Therapeutics
PTCT
$5.68B
$4.45M 100%
262,069
-154,597
-37% -$2.72M
CELGZ
2
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
– –
-1,399,919
Closed -$11.2M

Similar funds

OHCM
Orchard Hill Capital Management New York $22.6M AUM 3.52% 1-Year Est. Return
AC
Altus Capital Mayfield Heights, Ohio $22.6M AUM 34.75% 1-Year Est. Return
IT
Investors Trust Dallas, Texas $32M AUM 1.92% 1-Year Est. Return
WA
Whippoorwill Associates White Plains, New York $19.3M AUM 10.09% 1-Year Est. Return
MCM
Martin Capital Management Elkhart, Indiana $36.5M AUM 4.02% 1-Year Est. Return
ADICC
Abu Dhabi Investment Council Co Abu Dhabi, United Arab Emirates $16.7M AUM 8.06% 1-Year Est. Return
SC
Sumit Capital New York $16.6M AUM 9.66% 1-Year Est. Return
3NC
300 North Capital Pasadena, California $16.3M AUM 27.56% 1-Year Est. Return

Ayer Capital Management's Q4 2013 Portfolio in Review

As of Q4 2013, Ayer Capital Management held 2 positions worth $4.45M, down 76% from $18.4M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Ayer Capital Management withdrew a net $13.9M in Q4 2013, closing 1 position and reducing 1 holding. Its most notable exit was Celgene Corporation Contingent Value Rights, an estimated $11.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 39% a quarter earlier.

  • Ayer Capital Management's biggest Q4 2013 reduction was PTC Therapeutics, cutting an estimated $2.72M.
  • Ayer Capital Management fully exited Celgene Corporation Contingent Value Rights in Q4 2013, selling an estimated $11.2M.
  • Ayer Capital Management's ten largest holdings make up 100% of its $4.45M portfolio in Q4 2013.
  • Ayer Capital Management opened 0 new positions and closed 1 in Q4 2013.
  • Ayer Capital Management's portfolio value fell 76% quarter-over-quarter to $4.45M.

Based on Ayer Capital Management's 13F filing for Q4 2013, filed 18 Feb 2014.